<DOC>
	<DOCNO>NCT00583518</DOCNO>
	<brief_summary>The primary objective study explore relationship new image technology ( ImaTx ) , analyze trabecular structure bone use digitize radiograph bone mineral density ( BMD ) measure Dual X-ray Absorptiometry ( DXA ) lumbar spine postmenopausal ( PM ) woman osteoporosis ( OP ) treatment PTH ( 1-84 ) .</brief_summary>
	<brief_title>STEP : Study Imaging Techniques ( ImaTx DXA ) Postmenopausal Women With OstEoporosis Using Preotact ( FP-008-ES )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>1 . Has subject give informed consent accord local requirement trialrelated activity ? A trialrelated activity procedure would perform routine management subject . 2 . Is subject female ? 3 . Is subject 65 year old ? 4 . Is subject postmenopausal ( 5 year ) , judgement investigator ? 5 . Does subject primary osteoporosis , lumbar spine T score ≤ 3.0 SD , lumbar spine Tscore ≤ 2.5 SD previous fragility fracture [ 1 ] , minimum two evaluable lumbar vertebra ? 6 . Does subject life expectancy &gt; 2 year ? 7 . Does subject clinical indication receive PTH ( 184 ) able selfinject ( PTH ( 184 ) injection helper ) ? All inclusion criterion must answer `` yes '' subject participate trial . [ 1 ] Definition fragility fracture scope study : Bone fracture occur result fall stand height less . That , fracture result mechanical force would ordinarily cause fracture healthy person . 1 . Is patient currently take follow treatment : bisphosphonates , selective estrogen receptor modulators hormone replacement therapy ( patient discontinues treatment screen visit , question answer NO patient include ) ? 2 . Has subject receive , lifetime , strontium , fluoride calcitonin &gt; 3 month total ? 3 . Has subject ever treat teriparatide PTH ( 184 ) ? 4 . Is subject take medication know affect bone metabolism opinion investigator ? 5 . Has subject ever receive radiation therapy skeleton ? 6 . Has subject ever treat bone malignant disease ? 7 . Is subject suffer know clinically significant disease affect calcium metabolism , include metabolic bone diseases hyperparathyroidism , Paget 's disease , osteogenesis imperfecta , osteomalacia ? 8 . Does subject know history hypersensitivity parathyroid hormone excipients drug ? 9 . Does subject elevate serum calcium ( total serum calcium value &gt; 10.2 mg/dl ) least 14 day 1000 mg calcium 800 IU vitamin D3 supplementation ? 10 . Does subject clinically significant elevation serum alkaline phosphatase judge investigator ? 11 . Does subject impair kidney function creatinine clearance &lt; 30ml/min ( indirect measurement serum creatinine ) ? 12 . Does subject severe hepatic impairment , define &gt; 9 ChildPugh score ? 13 . Has subject participate clinical trial Investigational Medicinal Product ( IMP ) last 30 day ? 14 . Does subject bilateral hip replacement ? All exclusion criterion must answer `` '' subject participate trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>